A detailed history of Partners Capital Investment Group, LLP transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Partners Capital Investment Group, LLP holds 254,845 shares of ALLO stock, worth $476,560. This represents 0.01% of its overall portfolio holdings.

Number of Shares
254,845
Previous 454,845 43.97%
Holding current value
$476,560
Previous $1.06 Million 32.67%
% of portfolio
0.01%
Previous 0.02%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$2.08 - $3.5 $416,000 - $700,000
-200,000 Reduced 43.97%
254,845 $713,000
Q2 2024

Aug 13, 2024

BUY
$2.23 - $4.38 $806,361 - $1.58 Million
361,597 Added 387.78%
454,845 $1.06 Million
Q1 2024

May 14, 2024

SELL
$2.92 - $5.63 $1.06 Million - $2.04 Million
-361,597 Reduced 79.5%
93,248 $416,000
Q2 2023

Aug 14, 2023

BUY
$4.53 - $6.74 $1.64 Million - $2.44 Million
361,597 Added 387.78%
454,845 $2.26 Million
Q2 2021

Aug 16, 2021

SELL
$23.49 - $35.8 $293,765 - $447,714
-12,506 Reduced 11.83%
93,248 $2.43 Million
Q1 2021

May 17, 2021

SELL
$25.79 - $39.02 $645,059 - $975,968
-25,012 Reduced 19.13%
105,754 $3.73 Million
Q4 2020

Feb 16, 2021

SELL
$25.24 - $43.45 $157,825 - $271,692
-6,253 Reduced 4.56%
130,766 $3.3 Million
Q3 2020

Nov 13, 2020

SELL
$32.38 - $44.96 $377,065 - $523,559
-11,645 Reduced 7.83%
137,019 $5.17 Million
Q2 2020

Aug 12, 2020

SELL
$18.39 - $54.04 $337,015 - $990,337
-18,326 Reduced 10.97%
148,664 $6.37 Million
Q1 2020

May 14, 2020

SELL
$18.22 - $28.25 $305,367 - $473,470
-16,760 Reduced 9.12%
166,990 $3.25 Million
Q4 2019

Feb 13, 2020

BUY
$24.82 - $31.4 $4.56 Million - $5.77 Million
183,750 New
183,750 $4.77 Million

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $269M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Partners Capital Investment Group, LLP Portfolio

Follow Partners Capital Investment Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Partners Capital Investment Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Partners Capital Investment Group, LLP with notifications on news.